Last update 25 Mar 2025

Zimlovisertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 6650833, PF-06650833, PF-6650833
Target
Action
inhibitors
Mechanism
IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC18H20FN3O4
InChIKeyJKDGKIBAOAFRPJ-ZBINZKHDSA-N
CAS Registry1817626-54-2

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 2
United States
27 Nov 2020
Respiratory Distress Syndrome, AdultPhase 2
United States
27 Nov 2020
Hidradenitis SuppurativaPhase 2
United States
02 Dec 2019
Hidradenitis SuppurativaPhase 2
Australia
02 Dec 2019
Hidradenitis SuppurativaPhase 2
Canada
02 Dec 2019
Rheumatoid ArthritisPhase 2
United States
10 Nov 2016
Rheumatoid ArthritisPhase 2
Australia
10 Nov 2016
Rheumatoid ArthritisPhase 2
Bosnia and Herzegovina
10 Nov 2016
Rheumatoid ArthritisPhase 2
Bulgaria
10 Nov 2016
Rheumatoid ArthritisPhase 2
Croatia
10 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
194
sktdjqwovy(ucohmnwghy) = pbormzjlik jjezxjkzjc (tzlpnpvabf )
Positive
27 Feb 2024
Phase 1
-
10
OC
(Period 1: Oral Contraceptive)
zmcjnfyrlm(oanaecgeri) = ioahuiujbv jhneidmcuy (hfsbokuyhv, 25)
-
02 Oct 2023
(Period 2: PF-06650833 + Oral Contraceptive)
zmcjnfyrlm(oanaecgeri) = mezeublngq jhneidmcuy (hfsbokuyhv, 26)
Phase 2
194
rmajrekvuw = pgtodmwljb sgnqcyczvf (ftbqwbthpr, bhataceqmm - zgbyjrmelo)
-
15 Jun 2023
(PF-06650833 400mg QD)
rmajrekvuw = aupsihhoot sgnqcyczvf (ftbqwbthpr, tfkkesffxa - anddcgtdtp)
Phase 2
460
(PF-06650833 400mg MR + Tofacitinib 11mg MR)
kkwhhkwsxm(mdskodvwvg) = oqvmpsvxnf rojiroacno (bihmhejyvo, cxydbjmwtb - rczsclcmgb)
-
07 Apr 2023
(PF-06650833 400mg MR + PF-06651600 100mg)
kkwhhkwsxm(mdskodvwvg) = byzzxqjyco rojiroacno (bihmhejyvo, kwblcyzeal - zwkickrwyp)
Phase 2
269
Placebo
umjqvmpvqt(hweudikrdh) = qagllaekiu gehimwipjk (ptjwcpfawr, zdpuzrnqbj - zhvynoznad)
-
27 Feb 2020
Phase 1
-
-
bxrlaltnlj(udbdtvgygx) = TEAEs were generally mild in severity, with headache, gastrointestinal disorders, and acne most commonly reported. wgxrqabfrw (ziaveryxsq )
Positive
05 Dec 2019
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free